Company news
TG Therapeutics, Inc. news in 2020
TG Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.
TG Therapeutics Announces Proposed Public Offering of Common Stock
December 13, 2020
TG Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
December 13, 2020
TG Therapeutics Announces Positive Topline Results from the ULTIMATE I & II Phase 3 Studies Evaluating Ublituximab Monotherapy for the Treatment of Patients with Multiple Sclerosis
December 9, 2020
TG Therapeutics Announces Triple Combination Data Presentations at the at the 62nd American Society of Hematology Annual Meeting
December 6, 2020
TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting
December 6, 2020
TG Therapeutics Recaps Schedule of Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
December 2, 2020
TG Therapeutics Announces Publication of Phase 2 Data Evaluating Umbralisib in Patients with Chronic Lymphocytic Leukemia Who Are Intolerant to Prior BTK or PI3K Inhibitor Therapy in Blood
December 1, 2020
TG Therapeutics Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration for Ublituximab in Combination with Umbralisib as a Treatment for Patients with Chronic Lymphocytic Leukemia
November 30, 2020
TG Therapeutics to Participate in the 3rd Annual Evercore ISI HealthCONx Conference
November 29, 2020
TG Therapeutics to Participate in the Jefferies Virtual London Healthcare Conference
November 12, 2020
TG Therapeutics Provides Business Update and Reports Third Quarter 2020 Financial Results
November 8, 2020
TG Therapeutics Highlights Data Selected for Presentation at the 62nd American Society of Hematology (ASH) Annual Meeting
November 3, 2020
TG Therapeutics Announces Data Presentations at the Upcoming 62nd American Society of Hematology Annual Meeting and Exposition
November 1, 2020
TG Therapeutics Announces Fast Track Designation Granted by the FDA to Ublituximab in Combination with Umbralisib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia
October 20, 2020
TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma
August 12, 2020
TG Therapeutics Provides Business Update and Reports Second Quarter 2020 Financial Results
August 9, 2020
TG Therapeutics to Host Conference Call on Second Quarter 2020 Financial Results and Business Update
August 5, 2020
TG Therapeutics Announces Publication in Blood Advances Describing Unique Immunomodulatory Effects on CLL T cells by Umbralisib
July 7, 2020
TG Therapeutics Announces Preclinical Data Presentation at the 2020 American Association for Cancer Research Annual Meeting
June 21, 2020
TG Therapeutics Completes Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
June 16, 2020
TG Therapeutics to Present at the Raymond James 2020 Human Health Innovation Conference
June 15, 2020
TG Therapeutics Announces Data Presentations at the 25th European Hematology Association (EHA) Annual Congress
June 11, 2020
TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
June 8, 2020
TG Therapeutics to Present at the Jefferies 2020 Healthcare Conference
June 1, 2020
TG Therapeutics Announces Final Results of the GENUINE Phase 3 Study Evaluating Ublituximab plus Ibrutinib in Previously Treated High-Risk Chronic Lymphocytic Leukemia at the 56th American Society of Clinical Oncology Annual Meeting
May 28, 2020
TG Therapeutics Announces Preclinical Data Presentation at the Upcoming American Association for Cancer Research Annual Meeting
May 14, 2020
TG Therapeutics Provides Business Update and Reports First Quarter 2020 Financial Results
May 10, 2020
TG Therapeutics Strengthens Executive Team with the Addition of Owen A. O’Connor, MD, PhD, as Chief Scientific Officer
May 7, 2020
TG Therapeutics Raises Approximately $60 Million in Gross Proceeds Through its At-the-Market Facility
May 5, 2020
TG Therapeutics Announces Positive Topline Results from the UNITY-CLL Phase 3 Study Evaluating the Combination of Umbralisib and Ublituximab (U2) for the Treatment of Patients with Chronic Lymphocytic Leukemia
May 4, 2020
TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal
April 30, 2020
TG Therapeutics Bolsters Board of Directors with the Appointment of Sagar Lonial, MD
April 28, 2020
TG Therapeutics Announces Data Presentations at the Upcoming American Academy of Neurology 72nd Annual Meeting
March 8, 2020
TG Therapeutics Receives Orphan Drug Designation for Umbralisib from the U.S. Food and Drug Administration for the Treatment of Follicular Lymphoma
March 4, 2020
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2019 Financial Results
March 2, 2020
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2019 Financial Results and Business Update
February 27, 2020
TG Therapeutics Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma or Follicular Lymphoma
January 15, 2020
Calls in 2020
Decks in 2020
- Investor Presentation (October 2020)
Investor deck · 21 slides · October 2020